• Home
  • Agric
  • Sci & Tech
  • Health
  • Environment
  • Hausa News
  • More
    • Business/Banking & Finance
    • POLITICS
    • Entertainments & Sports
    • International
    • Investigation
    • Law & Human Rights
    • Africa
    • ACCOUNTABILITY/CORRUPTION
    • Hassan Gimba
    • Column
    • Prof. Jibrin Ibrahim
    • Prof. M.K. Othman
    • Defense/Security
    • Education
    • Energy/Electricity
    • Entertainment/Arts & Sports
    • Society and Lifestyle
    • Food & Agriculture
    • Health & Healthy Living
    • International News
    • Interviews
    • Investigation/Fact-Check
    • LAW & HUMAN RIGHTS
    • Oil & Gas/Mineral Resources
    • PRESS FREEDOM/JOURNALISM/PR
    • General News
    • Presidency
  • About Us
    • Contact Us
    • Board Of Advisory
    • Privacy Policy
    • Ethics Policy
    • Teamwork And Collaboration Policy
    • Fact-Checking Policy
    • Advertising
  • Media OutReach Newswire
    • Wire News
  • The Stories
Facebook Twitter Instagram
Trending
  • Dangote: Reliable electricity critical to industrial growth, urges entrepreneurs to build around investments
  • Nigerian journalist remanded over reports on alleged ₦147m SDG project
  • CBN moves to strengthen credit guarantees, boost private-sector agricultural financing
  • Lagos reaffirms food security push
  • Yargote foundation seeks more support for boy-child programme
  • Foundation unveils public sector reform playbook
  • Blueprint aims to turn African farms Into industries
  • WHO warns insecurity Is hindering Ebola response
Facebook Twitter Instagram YouTube
AsheNewsAsheNews
  • Home
  • Agric

    CBN moves to strengthen credit guarantees, boost private-sector agricultural financing

    November 12, 2026

    Lagos reaffirms food security push

    November 12, 2026

    Blueprint aims to turn African farms Into industries

    November 12, 2026

    GOCOP brings food and supplies to Lagos Orphanage

    November 12, 2026

    New programme aims to connect farmers with expertise

    November 12, 2026
  • Sci & Tech

    Nigeria plans satellite facility in Epe

    November 12, 2026

    3MTT seeks partners to train Nigerians in digital skills

    November 12, 2026

    Expert urges Nigeria to build sovereign AI platform

    November 11, 2026

    NATCOMS flags cybersecurity risks in SPARK loan service

    November 11, 2026

    NITDA unveils 2026 Nigeria tech outlook report

    November 11, 2026
  • Health

    Yargote foundation seeks more support for boy-child programme

    November 12, 2026

    WHO warns insecurity Is hindering Ebola response

    November 12, 2026

    Expert seeks more funding for animal health research

    November 12, 2026

    Kaduna health insurance costs N10,650 annually

    November 12, 2026

    NAPTIP launches school clubs to fight human trafficking

    November 11, 2026
  • Environment

    COP31: Why governments must confront systems exploiting women and Earth, by Melania Chiponda

    November 11, 2026

    FUTA Don urges sustained advocacy against deforestation, technology to assess termite risks

    November 11, 2026

    Igando dumpsite reopening set to ease Lagos waste crisis

    November 11, 2026

    COP31: UN chief urges faster shift away from fossil fuels

    November 11, 2026

    Amnesty urges oil firms to fund Niger Delta environmental cleanup

    November 11, 2026
  • Hausa News

    Foundation unveils public sector reform playbook

    November 12, 2026

    Tinubu asks Reps to approve N10.79tn external borrowing for 2026 budget

    November 11, 2026

    UNA signs MoU to launch air Bissau in Guinea-Bissau

    June 15, 2026

    Otti plans 250-room 5-star hotel in Umuahia

    April 11, 2026

    Anti-quackery task force seals 4 fake hospitals in Rivers

    August 29, 2025
  • More
    1. Business/Banking & Finance
    2. POLITICS
    3. Entertainments & Sports
    4. International
    5. Investigation
    6. Law & Human Rights
    7. Africa
    8. ACCOUNTABILITY/CORRUPTION
    9. Hassan Gimba
    10. Column
    11. Prof. Jibrin Ibrahim
    12. Prof. M.K. Othman
    13. Defense/Security
    14. Education
    15. Energy/Electricity
    16. Entertainment/Arts & Sports
    17. Society and Lifestyle
    18. Food & Agriculture
    19. Health & Healthy Living
    20. International News
    21. Interviews
    22. Investigation/Fact-Check
    23. LAW & HUMAN RIGHTS
    24. Oil & Gas/Mineral Resources
    25. PRESS FREEDOM/JOURNALISM/PR
    26. General News
    27. Presidency
    Featured
    Recent

    Dangote: Reliable electricity critical to industrial growth, urges entrepreneurs to build around investments

    November 12, 2026

    Nigerian journalist remanded over reports on alleged ₦147m SDG project

    November 12, 2026

    CBN moves to strengthen credit guarantees, boost private-sector agricultural financing

    November 12, 2026
  • About Us
    1. Contact Us
    2. Board Of Advisory
    3. Privacy Policy
    4. Ethics Policy
    5. Teamwork And Collaboration Policy
    6. Fact-Checking Policy
    7. Advertising
    Featured
    Recent

    Dangote: Reliable electricity critical to industrial growth, urges entrepreneurs to build around investments

    November 12, 2026

    Nigerian journalist remanded over reports on alleged ₦147m SDG project

    November 12, 2026

    CBN moves to strengthen credit guarantees, boost private-sector agricultural financing

    November 12, 2026
  • Media OutReach Newswire
    • Wire News
  • The Stories
AsheNewsAsheNews
Home»Health & Healthy Living»FDA approves first 100% effective HIV prevention drug
Health & Healthy Living

FDA approves first 100% effective HIV prevention drug

Abdallah el-KurebeBy Abdallah el-KurebeJuly 29, 2025Updated:July 29, 2025No Comments4 Mins Read
Share
Facebook Twitter LinkedIn Pinterest Email

A 44-year-long epidemic could soon be brought under control, following the groundbreaking approval of the first HIV drug offering 100% protection through twice-yearly injections. This landmark medical achievement holds the potential to save millions of lives worldwide. Furthermore, its manufacturers are ensuring affordable global access by entering into royalty-free licensing agreements with six generic drug producers for its manufacture and distribution.

In the United States, the Food and Drug Administration (FDA) recently granted approval to lenacapavir, marketed as Yeztugo. This innovative drug belongs to a class called capsid inhibitors, offering near-complete protection against HIV infection, a condition that currently impacts 1.3 million individuals annually in the US.

Recognized as the “Breakthrough Invention of the Year” by the journal Science in 2024, lenacapavir has garnered significant attention during its development. As a pre-exposure prophylaxis (PrEP) medication, it offers approximately 99% protection for HIV-negative individuals against contracting the virus through sexual contact.

Lenacapavir functions as a capsid inhibitor. Within the HIV-1 virus, the capsid is a protective protein shell enclosing the viral genetic material; it is essential for transporting the virus into a host cell. Once inside, the capsid disassembles, allowing the virus to replicate. Lenacapavir prevents this crucial step.

Upon news of the FDA’s approval, Daniel O’Day, Chairman and CEO of Gilead Sciences, hailed it as “a historic day in the decades-long fight against HIV.” He emphasized that Yeztugo represents “one of the most important scientific breakthroughs of our time,” offering a tangible chance to “help end the HIV epidemic.” O’Day further noted the drug’s potential to “transform HIV prevention,” given its remarkable clinical trial outcomes and twice-yearly dosing schedule. “Gilead scientists have made it their life’s work to end HIV,” he added, expressing confidence that, with FDA approval and collaborative partnerships, this objective can now become a reality.

hiv

Previously, in 2022, lenacapavir was approved under the brand name Sunlenca for treating individuals already infected with HIV. However, developing a long-acting medication specifically for prevention has posed a significantly greater challenge.

Dr. Carlos del Rio, Distinguished Professor of Medicine at Emory University School of Medicine and Co-Director of the Emory Center for AIDS Research, stated that “Yeztugo could be the transformative PrEP option we’ve been waiting for.” He believes it will “boost PrEP uptake and persistence,” providing a vital new instrument in the fight against HIV. Dr. del Rio underscored that a twice-yearly injection could overcome major obstacles such as adherence issues and the stigma associated with more frequent PrEP regimens, particularly daily oral pills. He also noted that research shows a strong preference for less frequent dosing among individuals seeking PrEP.

Beyond the US, Gilead has sought regulatory approval in Australia, Brazil, Canada, South Africa, and Switzerland, with further applications planned for Argentina, Mexico, and Peru. Domestically, the company has taken steps to ensure Yeztugo’s affordability; eligible uninsured individuals may receive the drug free of charge via its Advancing Access medication assistance program.

Earlier this month, Gilead announced a collaboration with the Global Fund to Fight AIDS, Tuberculosis, and Malaria (Global Fund). This partnership aims to supply sufficient doses of the drug to reach up to two million people over three years in Global Fund-supported nations, with Gilead providing the medication at no profit. Additionally, license-free generic versions of the drug will be produced for distribution in 120 “high-incidence, resource-limited countries,” primarily low- and lower-middle-income nations.

This vital commitment to prioritizing widespread access over corporate profit represents a bold and commendable strategy for a pharmaceutical company, acknowledging the urgent global need to eradicate the HIV epidemic.

Daniel O’Day, Gilead Sciences’ Chairman and CEO, reaffirmed that the agreement with the Global Fund stems from a “shared intention to benefit as many people as possible, as quickly as possible” with this preventive breakthrough. He stated that Gilead is supplying the medicine “at no profit” and in quantities sufficient to reach up to two million individuals in low- and lower-middle-income countries before generic versions become available. O’Day characterized this as an “unprecedented approach to access for a medicine that could help end the HIV epidemic.”

The Global Fund is now collaborating with various international organizations to swiftly establish the necessary infrastructure and resources for delivering lenacapavir to countries most in need, particularly middle- and low-income nations. Peter Sands, Executive Director of the Global Fund, declared, “This is not just a scientific breakthrough – it’s a game-changer for HIV/AIDS.” He further emphasized, “For the first time, we have a tool that can fundamentally change the trajectory of the epidemic.”

Source: Gilead Sciences

FDA HIV AIDS HIV Prevention Lenacapavir Yeztugo
Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Abdallah el-Kurebe
  • Website
  • Facebook
  • Twitter
  • LinkedIn

Related Posts

Yargote foundation seeks more support for boy-child programme

November 12, 2026

WHO warns insecurity Is hindering Ebola response

November 12, 2026

Expert seeks more funding for animal health research

November 12, 2026

Leave A Reply Cancel Reply

Dangote: Reliable electricity critical to industrial growth, urges entrepreneurs to build around investments

November 12, 2026

Nigerian journalist remanded over reports on alleged ₦147m SDG project

November 12, 2026

CBN moves to strengthen credit guarantees, boost private-sector agricultural financing

November 12, 2026

Lagos reaffirms food security push

November 12, 2026
About Us
About Us

ASHENEWS (AsheNewsDaily.com), published by PenPlus Online Media Publishers, is an independent online newspaper. We report development news, especially on Agriculture, Science, Health and Environment as they affect the under-reported rural and urban poor.

We also conduct investigations, especially in the areas of ASHE, as well as other general interests, including corruption, human rights, illicit financial flows, and politics.

Contact Info:
  • 1st floor, Dogon Daji House, No. 5, Maiduguri Road, Sokoto
  • +234(0)7031140009
  • ashenewsdaily@gmail.com
Facebook Twitter Instagram Pinterest
© 2026 All Rights Reserved. ASHENEWS Daily Designed & Managed By DeedsTech

Type above and press Enter to search. Press Esc to cancel.